• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Compositions for the skin. The present invention relates to a composition comprising hyaluronic acid, dermatan sulfate, at least one omega-3 fatty acid and at least one nucleotide. It also refers to the composition for use in the treatment or prevention of diseases, conditions, dysfunctions or alterations of the skin, preferably of atopic dermatitis. The composition may be in the form of a pharmaceutical composition, food supplement, functional food or medical food. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2638195A1
    申请号:ES201630479
    申请日:2016-04-18
    公开日:2017-10-19
    发明作者:José ESCAICH FERRER；Sergi SEGARRA LÓPEZ；Javier CÓRDOBA LUCIO；Jorge FLORES GARCÍA；Alfonso VELASCO FRANCO
    申请人:Bioiberica SA；
    IPC主号:
    专利说明:

    5
    10
    fifteen
    twenty
    25
    30
    35
    DESCRIPTION Compositions for the skin Technical sector of the invention
    The present invention relates to a composition. Similarly, it refers to the composition for use in the treatment or prevention of diseases, conditions, dysfunctions or alterations of the skin, especially atopic dermatitis, as well as in restoring the integrity of the skin. The compositions may be in the form of pharmaceutical compositions, food supplements, functional foods or medical foods.
    State of the prior art
    Atopic dermatitis is a chronic inflammatory dermatosis characterized by pruritic and scaling rashes. It is a multifactorial disease that results from the interaction of genetic factors, defects in barrier function, environmental factors, susceptibility to skin infections and a series of immunological factors. It is a fundamentally childhood disease, but it can persist into adulthood.
    Atopic dermatitis is a fairly common disease in companion animals. The fact of the existence of a racial predisposition in dogs suggests the great importance of genetic factors.
    Fibroblasts are, together with keratinocytes, the main cells of the dermis and epidermis. Its migration and proliferation are involved in the re-epithelialization process, very necessary in dermal pathologies in which the dermal barrier is altered and the patients present lesions caused by the pathology itself or by self-scratching due to pruritus. In fact, it is known that fibroblasts are involved in the pathogenesis of atopic dermatitis (A. Berroth et al., J. Allergy Clin. Immunol. 131 (6), 1547-1554 (2013)).
    Steroids, antihistammics or antibiotics are usually prescribed for the treatment of atopic dermatitis. If these drugs are used for a long period of time, some unwanted side effects may occur.
    Therefore, a composition is required for the effective treatment of atopic dermatitis, without side effects.
    5
    10
    fifteen
    twenty
    25
    30
    35
    Polyunsaturated fatty acids (in English Poly Unsaturated Fatty Acids (PUFA)) are fatty acids that contain more than a double bond between their carbons. They are involved in important metabolic pathways in living things. They can be obtained from blue fish and vegetables such as nuts, corn, sunflower or soy. Two series of polyunsaturated fatty acids, the omega-3 series and the omega-6 series, should be highlighted. Omega-3 fatty acids have beneficial effects on risk factors for cardiovascular diseases, for example hypertension, hypertriglyceridemia and hypercholesterolemia. Among omega-3 fatty acids, it is worth mentioning eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and among omega-6 fatty acids, gamma-linolenic acid (GLA).
    The efficacy of omega-3 and omega-6 fatty acids in the treatment of atopic dermatitis is known. Patent application WO 2015/040067 describes a composition for atopic dermatitis containing gamma-linolenic fatty acid and eicosapentaenoic fatty acid. RS Mueller et al. describe the efficacy of omega-3 fatty acids in canine atopic dermatitis (J. Small Anim. Pract. 45 (6), 293-297 (2004)).
    Glycosaminoglycans (GAGs) are high molecular weight polymeric biomolecules formed by repeats of a disacaridic unit. They are found primarily in living organisms, where they develop different physiological functions.
    Hyaluronic acid is a non-sulfated glycosaminoglycan, with a polymeric structure characterized by a repeating disaccharide, consisting of N-acetyl-D-glucosamine monosaccharides and D-glucuronic acid. It is one of the main components of cartilage, synovial membrane and synovial fluid. In particular, its use is important in the treatment of joint dysfunctions such as osteoarthritis, usually intra-articularly. Its use has also been described in ophthalmology, in wound healing, as well as in cosmetics.
    Dermatan sulfate is a sulfated glycosaminoglycan with a polymeric structure consisting mostly of N-acetyl-D-galactosamine sulfated disaccharides in position 4 and L-iduronic acid, often sulphated in position 2. It has been described that it participates in the repair of wounds and in the regulation of blood coagulation. US 7,763,594 describes the use of a composition of hyaluronic acid and dermatan sulfate to treat osteoarthritis.
    5
    10
    fifteen
    twenty
    25
    30
    35
    Nucleotides are low molecular weight intracellular compounds that play a role in virtually all biochemical processes. They are present naturally in food although in limited quantities (<400mg / 100g). Tissues that have high rates of cell proliferation, such as those of the immune system or the intestine, are unable to cover their nucleotide needs exclusively using de novo synthesis, so that they preferably use the nucleotide recovery pathway of the diet. It has been described that in situations of immune stress (patients in critical situations) dietary supplementation with nucleotide formulations is essential to maintain the humoral and cellular response of the immune system (A. Gil, European Journal of Clinical Nutrition, 56 suppl 3, S1 -S4 (2002)). Specifically, it has been shown that exogenous nucleotide supplementation stimulates lymphoid cell proliferation and lymphoproliferative response to alloantigens and mitogens. In addition, this supplementation contributes to the response of T lymphocytes, increases the response of delayed cutaneous hypersensitivity, increases graft rejection, reverses the immunosuppression associated with malnutrition, increases resistance to certain infections, regulates the amount of natural killer cells ”(NK) and macrophages, and promotes immunoglobulin synthesis (J. Maldonado et al, Early Human Development, 65 Suppl., S69-S74 (2001)).
    Zinc oxide (ZnO) is used to protect the skin from the harmful effects of ultraviolet rays. Its effectiveness in wound healing is also described (patent EP 1064946).
    The collagen hydrolyzate is constituted by a mixture of amino acids and peptides of low molecular weight. It is obtained by controlled enzymatic hydrolysis of the collagenous protein contained in the skin and other connective tissues. It is mostly used in cosmetics.
    To date, the combination of the components of the compositions of the present invention has not been described.
    Explanation of the invention
    The present inventors have found that the compositions of the present invention, defined below, have an inducing effect of the proliferation of human dermal fibroblasts and have no cellular toxicity. Therefore, they can be used in the treatment or prevention of a disease or skin lesion selected from the group consisting of atopic dermatitis, allergic dermatitis, demodicosis, psoriasis, wound, ulcer and burn. They can also be used to restore the integrity of the skin during or after a dermatitis or demodicosis, prevent or reverse a psoriasic lesion, increase the
    4
    5
    10
    fifteen
    twenty
    25
    30
    35
    hydration and flexibility of the skin, prevent the formation of a wound or an ulcer or improve the quality of healing of a wound, an ulcer or a burn in a mammal.
    Accordingly, the present invention relates to a composition comprising hyaluronic acid, dermatan sulfate, at least one omega-3 fatty acid and at least one nucleotide.
    In a preferred embodiment, omega-3 fatty acid and hyaluronic acid are present in a weight ratio omega-3 fatty acid to hyaluronic acid between 100: 0.50 and 100: 5, preferably between 100: 0.50 and 100: 2.50. More preferably the weight ratio is 100: 1.13.
    In another preferred embodiment, the omega-3 fatty acid and dermatan sulfate are present in a weight ratio omega-3 fatty acid to dermatan sulfate between 100: 0.10 and 100: 2, preferably between 100: 0 , 10 and 100: 1. More preferably the weight ratio is 100: 0.23.
    In another preferred embodiment, the omega-3 fatty acid and the nucleotide are present in a weight ratio omega-3 to nucleotide between 100: 20 and 100: 200, preferably between 100: 20 and 100: 100. More preferably, the weight ratio is 100: 52.44.
    Preferably, omega-3 fatty acid, hyaluronic acid, dermatan sulfate and nucleotide are present in a weight ratio omega-3 fatty acid to hyaluronic acid to dermatan sulfate to nucleotide between 100: 0.50: 0 , 10: 20 and 100: 5: 2: 200. preferably between 100: 0.50: 0.10: 20 and 100: 2.50: 1: 100. Especially preferred is the weight ratio 100: 1.13: 0.23: 52.44.
    In another preferred embodiment, the composition further comprises a zinc compound. Preferably zinc oxide.
    In another equally preferred embodiment, the omega-3 fatty acid and zinc oxide are present in a weight ratio of omega-3 fatty acid to zinc oxide between 100: 1 and 100: 10. Preferably between 100: 1 and 100: 5. More preferably the weight ratio is 100: 2.42.
    5
    10
    fifteen
    twenty
    25
    30
    35
    Preferably, omega-3 fatty acid, hyaluronic acid, dermatan sulfate, nucleotide and zinc oxide are present in a weight ratio omega-3 fatty acid to hyaluronic acid to dermatan sulfate to nucleotide to zinc oxide between 100: 0.50: 0.10: 20: 1 and 100: 5: 2: 200: 10. Preferably between 100: 0.50: 0.10: 20: 1 and 100: 2.50: 1: 100: 5. Especially preferred is the weight ratio 100: 1.13: 0.23: 52.44: 2.42.
    In another equally preferred embodiment, the composition further comprises at least one omega-6 fatty acid.
    The omega-3 fatty acid and the omega-6 fatty acid are present in a weight ratio omega-3 to omega-6 fatty acid between 1: 0.05 and 1: 1, preferably the weight ratio is 1: 0.13.
    Preferably, omega-3 fatty acid, hyaluronic acid, dermatan sulfate, nucleotide, zinc oxide and omega-6 fatty acid are present in a weight ratio omega-3 to hyaluronic acid to sulfate of Dermatane to nucleotide to zinc oxide to omega-6 fatty acid between 100: 0.50: 0.10: 20: 1: 5 and 100: 5: 2: 200: 10: 100. Especially preferred is the weight ratio 100: 1.13: 0.23: 52.44: 2.42: 13.
    In another preferred embodiment, the omega-3 fatty acid is selected from the group consisting of eicosapentaenoic acid, docosahexaenoic acid, alpha-linolenic acid, stearidonic acid, eicosatetraenoic acid, heneicosapentaenoic acid, docosapentaenoic acid and mixtures thereof. The most preferred is eicosapentaenoic acid.
    In another equally preferred embodiment, the omega 6 fatty acid is selected from the group consisting of gamma-linolenic acid, linoleic acid and mixtures thereof. The most preferred is gamma-linolenic acid.
    Preferably the weight ratio of eicosapentaenoic acid to gamma-linolenic acid is 1: 0.075.
    Preferably, the concentration of eicosapentaenoic acid is between 50% and 90% by weight, based on the total weight of omega-3 fatty acids present in the composition. More preferably it is 70%.
    Preferably, the concentration of gamma-linolenic acid is comprised between a
    6
    5
    10
    fifteen
    twenty
    25
    30
    35
    20% and 60% by weight, based on the total weight of omega-6 fatty acids present in the composition. More preferably it is 40%.
    Preferably, the nucleotide is obtained from a yeast. More preferably Saccharomices cerevisiae.
    In another equally preferred embodiment, the composition also comprises collagen hydrolyzate.
    Collagen hydrolyzate contains amino acids and low molecular weight peptides.
    In another equally preferred embodiment, the composition also comprises vitamin E.
    The present invention also relates to a food supplement, a functional food or a medical food comprising the composition, defined above, and at least one nutritional additive.
    Likewise, the present invention also relates to a pharmaceutical composition comprising the composition, defined above, and at least one pharmaceutically acceptable excipient.
    Likewise, the present invention also relates to a composition, defined above, for use as a medicament or medical food.
    The present invention also relates to a composition, defined above, for use in the treatment or prevention of a disease or lesion of the skin selected from the group consisting of atopic dermatitis, allergic dermatitis, demodicosis, psoriasis, wound, ulcer and burn in a mammal.
    Likewise, the present invention also relates to a medical food containing a composition, defined above, for use in restoring the integrity of the skin during or after dermatitis or demodicosis, preventing or reversing a psoriasic lesion, increasing the hydration and flexibility of the skin, prevent the formation of a wound or an ulcer or improve the quality of healing of a wound, an ulcer or a burn in a mammal.
    5
    10
    fifteen
    twenty
    25
    30
    Likewise, the present invention also relates to a food supplement, functional food or medical food, for use in restoring the integrity of the skin during or after dermatitis or demodicosis, preventing or reversing a psoriasic lesion, increasing hydration. and flexibility of the skin, prevent the formation of a wound or an ulcer or improve the healing quality of a wound, an ulcer or a burn in a mammal.
    The present invention also relates to the use of a composition, defined above, for the preparation of a medicament for the treatment or prevention of a skin disease or injury selected from the group consisting of atopic dermatitis, allergic dermatitis, demodicosis, Psoriasis, wound, ulcer and burn in a mammal.
    Likewise, the present invention also relates to the use of a composition, defined above, for the preparation of a food supplement, a functional food or a medical food, to restore the integrity of the skin during or after dermatitis or demodicosis. , prevent or reverse a psoriasic lesion, increase the hydration and flexibility of the skin, prevent the formation of a wound or an ulcer or improve the quality of healing of a wound, an ulcer or a burn in a mammal.
    Likewise, the present invention also relates to the use of a composition, defined above, as a food supplement, functional food or medical food, to restore the integrity of the skin during or after a dermatitis or demodicosis, to prevent or reverse an injury. psoriasis, increase the hydration and flexibility of the skin, prevent the formation of a wound or an ulcer or improve the quality of healing of a wound, an ulcer or a burn in a mammal.
    Preferably, the mammal is a dog or a human.
    In the present invention, the term "comprises" should be interpreted so that it also includes the case of "consists only of" and that of "consists essentially of".
    In the present invention, when talking about hyaluronic acid and dermatan sulfate, any salt thereof is included, for example sodium, potassium or calcium salt.
    5
    10
    fifteen
    twenty
    25
    30
    35
    Preferably, the hyaluronic acid and dermatan sulfate of the compositions of the present invention are in the form of sodium salt.
    The omega-3 and omega-6 fatty acids of the compositions of the present invention may be in the form of acids or in the form of triglycerides. Both forms are included, although preferably they are in the form of triglycerides.
    In the present invention the following terms have the indicated meaning:
    "Functional food" refers to a food that, apart from its basic nutritional role from the material and energy point of view, is capable of providing a health benefit by containing one or more biologically active components or a combination of biologically active components Functional food is part of an individual's diet.
    "Food supplement" refers to a diet supplement that contains in concentrated form one or more nutrients or other biologically active components with nutritional or physiological effect beneficial to health. It is administered in the form of tablets, capsules or in any other dosage form .
    "Medical food" refers to a food administered to a patient under the instructions and supervision of a doctor. Such food is specific to the nutritional requirements of a patient who has a certain disease, discomfort or disorder. It is used in the United States and it usually comes in the form of food, although it can also be found in a dosage form. In Europe the equivalent of "medical food" is "dietary food for special medical uses", which is a food intended for a special diet, which has been prepared or formulated especially to fully or partially meet the nutritional needs of patients whose ability to ingest, digest, absorb, metabolize or excrete normal foods or certain nutrients thereof or metabolites is limited or deficient, or is altered, or that need other specific nutrients chemically, whose dietary treatment cannot be carried out only modifi When the normal diet, with other foods for a special diet, or through both. It can be in dosed form or not.
    The omega-3 and omega-6 fatty acids used in the compositions of the present invention are commercially available products. Thus, for example, to prepare the compositions of the present invention, the omega-3 fatty acids of the
    9
    5
    10
    fifteen
    twenty
    25
    30
    35
    KinOmega company (product code: 7010EE) and omega-6 fatty acids from De Wit Specialty Oils (product code: 41140).
    The hyaluronic acid and dermatan sulfate of the compositions of the present invention can be obtained by extractive procedures from tissues of birds or mammals or by biotechnology.
    The average molecular weights of hyaluronic acid and dermatan sulfate of the compositions of the present invention may vary depending on the process of obtaining. Preferably, the average molecular weight of hyaluronic acid is between 300,000 and 2,000,000 daltons, more preferably between 800,000 and 1,000,000 daltons and that of dermatan sulfate is between 10,000 and 50,000 daltons. In the present invention, the average molecular weights of hyaluronic acid and dermatan sulfate were determined by gel permeation chromatography (GPC).
    The hyaluronic acid of the compositions of the present invention can be obtained, by extraction, from the tissues of birds or mammals, for example from vortex humor, mammalian skin, umbilical cord or bird crests or by fermentation of microorganisms (for example Streptococcus), following procedures described in the literature (DA Swann, Biochim. Biophys. Acta 156, 17-30 (1968); US Patent 4,780,414).
    Preferably, the hyaluronic acid of the compositions of the present invention is a commercial product available in www.bioiberica.com It is obtained from rooster crests, which once chopped are digested with a proteolphic enzyme. The enzyme is subsequently deactivated by heating, filtered, the dermatan sulfate is removed and the hyaluronic acid is precipitated, which is anhydrified, dried and milled. Said hyaluronic acid in the form of sodium salt has a minimum richness of 90%, determined by glucuronic acid content, and an average molecular weight between 800,000 and 1,000,000 daltons.
    Dermatan sulfate of the compositions of the present invention can be obtained from poultry or mammalian tissues, for example from pig or bovine mucosa, bird crests or mammalian skin, following procedures described in the literature (N Volpi, Anal. Biochem. 218, 382-391 (1994); EP 238994).
    5
    10
    fifteen
    twenty
    25
    30
    35
    Preferably, the dermatan sulfate of the compositions of the present invention is obtained from rooster crests, in the process of obtaining hyaluronic acid. Once the dermatan sulfate is separated as a complex, the complex is broken by ionic strength, precipitated, anhydrified, dried and ground. It is also possible to use porcine mucosa dermatan sulfate marketed by Sigma-Aldrich Qwmica (product code: C3788). Dermatane sulfate in the form of sodium salt that comes from rooster crests has a minimum richness of 90%, determined by photometric titration, and an average molecular weight between 10,000 and 50,000 daltons.
    Examples of the nucleotides of the compositions of the present invention are adenosine 5'-monophosphate (AMP), guanosine 5'-monophosphate (GMP), uridine 5'-monophosphate (UMP), cytidine 5'-monophosphate (CMP), deoxythymidine 5'-monophosphate (dTMP), deoxycytidine 5'-monophosphate (dCMP), inosine 5'-monophosphate (IMP), as well as the corresponding diphosphates and triphosphates.
    Preferably, the nucleotides of the present invention are obtained from a yeast, more specifically from the yeast Saccharomices cerevisiae. Particularly they are obtained from RNA of the yeast Saccharomices cerevisiae. They can also be obtained from RNA from Torula utilis yeast. The method of obtaining consists in the extraction of RNA from the yeast, followed by purification and hydrolysis of the RNA. Nucleoforce®, Nucleoforce® Dogs, Nucleoforce® Piglets or Nucleoforce® Poultry® products, which are marketed by Bioiberica SA ( www.bioiberica.com), and which can be used in the present invention as a source of nucleotides, are obtained from RNA of the yeast Saccharomices cerevisiae. Other commercially available nucleotides can also be used, for example Ascogen®, Vannagen®, Ascosan®, Cheracoform® Bioracing® ( www.chemoforma.com), or Provesta® by Ohly ( www.ohly.com), or Nupro from Alltech ( www.alltech.com).
    Zinc oxide is a commercial product. In the compositions of the present invention, the one sold by Kirsch Pharma Espana (product code: 101217) can be used.
    The collagen hydrolyzate of the compositions of the present invention can be obtained from mammalian skin or cockscomb, following procedures described in the literature ("Final Report on the Safety Assessment of Hydrolyzed Collagen", Journal of the American College of Toxicology 4, No. 5, 199-221, Mary Ann Liebert, Inc., Publishers, (1985)).
    5
    10
    fifteen
    twenty
    25
    30
    35
    The compositions of the present invention can be prepared by mixing their individual components in the desired proportions.
    Several of the components of the compositions of the present invention can be obtained together. Thus, the combination hyaluronic acid, dermatan sulfate and collagen hydrolyzate can be obtained directly from poultry or mammalian tissues by an extractive procedure. Thus, for example, it is possible to start from frozen rooster crests, which once chopped are digested with a proteolytic enzyme. Subsequently, the enzyme is deactivated by heating, filtered and precipitated with solvents. By slightly modifying this procedure, the combination of hyaluronic acid and dermatan sulfate can be obtained.
    The composition of the most preferred invention is that comprising 57.97% of omega-3 fatty acids (O-3), 0.66% of hyaluronic acid (AH), 0.15% of dermatan sulfate (SD), 30.40% of nucleotides (N), 1.40% of zinc oxide (ZnO) and 7.60% of omega-6 (O-6) fatty acids (weight ratio O-3: AH: SD: N : ZnO: O-6 100: 1.13: 0.23: 52.44: 2.42: 13).
    The composition may also contain 1.82% of vitamin E.
    To use the compositions of the present invention in the treatment, prophylaxis or prevention of atopic dermatitis, allergic dermatitis, demodicosis, psoriasis, wound, ulcer or burn in a mammal, they are formulated in suitable pharmaceutical compositions, using conventional techniques and excipients or vehicles. , as described in Remington: The Science and Practice of Pharmacy 2000, edited by Lippincott Williams and Wilkins, 20th edition, Philadelphia. Pharmaceutical compositions comprise a therapeutically effective amount of a composition of the present invention and at least one pharmaceutically acceptable excipient for administration to the patient. Said pharmaceutical compositions can be administered to the patient in required doses. The administration of the pharmaceutical compositions can be carried out by different routes, for example, oral, intravenous, subcutaneous, intramuscular, sublingual, intradermal, nasal or topical. The pharmaceutical compositions of the invention include a therapeutically effective amount of a composition of the present invention, said amount depending on many factors, such as, for example, the physical state of the patient, age, sex, route of administration, frequency of administration or severity of the illness. Furthermore, it will be understood that said dosage of the composition of the invention can be administered in single or multiple dose units to provide the desired therapeutic effects.
    12
    5
    10
    fifteen
    twenty
    25
    30
    35
    The pharmaceutical compositions of the invention will generally be in solid, liquid or gel form. Solid pharmaceutical preparations that can be prepared in accordance with the present invention include powders, mini-granules (pellets), tablets, dispersible granules, capsules, seals, tablets, lyophilisates and suppositories. Liquid form preparations include solutions, suspensions, emulsions, syrups, elixirs, drinkable vials and herbal teas. Also contemplated are preparations of solid forms that are to be converted, immediately before being used, into preparations in liquid form. Such liquid forms include solutions, suspensions and emulsions.
    To use the compositions of the present invention in restoring the integrity of the skin during or after a dermatitis or demodicosis, preventing or reversing a psoriasic lesion, increasing the hydration and flexibility of the skin, preventing the formation of a wound or of an ulcer or improve the healing quality of a wound, an ulcer or a burn in a mammal, food supplements or dietary foods are prepared for special medical uses in dosed forms containing a composition of the invention and additives used in nutrition, either functional foods are prepared by adding the compositions of the invention to foods that are part of the diet, or medical foods or dietary foods are prepared for special medical uses in non-dosed forms containing a composition of the invention and nutrients or foods. The food supplement may be in the form of tablets, capsules, solutions, suspensions or sachets. The functional food may be in the form of yogurts, milk, fermented milk, fruit juices, vegetable juices, soups, creams, dehydrated foods, cookies or baby foods. The dietary food for special medical uses may be in the form of tablets, capsules, solutions, suspensions or sachets or also as food for the special feeding of patients. Medical food is usually presented in the form of food for patient feeding, although it can also be found in dosed form.
    The pharmaceutical compositions, food supplements, functional foods or medical foods of the present invention may also contain at least one vitamin, selected from the group consisting of vitamin C, vitamin E, vitamin A, folic acid, niacin, acid pantothenic, vitamin B2, vitamin B6, vitamin B12, vitamin D and biotin.
    5
    10
    fifteen
    twenty
    25
    30
    35
    Brief description of the Figures
    The effect of a composition of the invention containing omega-3 fatty acids, hyaluronic acid, dermatan sulfate and nucleotides (O-3 + AH + SD + N) and Figure 1 is shown at the concentration of 0.156 mg / mL. that of a composition containing omega-3 fatty acids, hyaluronic acid and dermatan sulfate (O-3 + AH + SD) on the percentage of proliferation of human dermal fibroblasts at 48 hours. Positive Control (culture of human dermal fibroblasts in the presence of TGF-P) and Basal Control (culture of human dermal fibroblasts in culture medium and in the absence of the compositions to be studied) are also included.
    The effect of a composition of the invention containing omega-3 fatty acids, hyaluronic acid, dermatan sulfate, nucleotides and zinc oxide (O-3 + AH + SD) is shown at the concentration of 0.078 mg / mL. + N + ZnO) and that of a composition containing omega-3 fatty acids, hyaluronic acid and dermatan sulfate (O-3 + AH + SD) on the percentage of human dermal fibroblast proliferation at 24 hours. Positive Control (culture of human dermal fibroblasts in the presence of TGF-P) and Basal Control (culture of human dermal fibroblasts in culture medium and in the absence of the compositions to be studied) are also included.
    Detailed description of preferred embodiments
    The following examples are for illustrative purposes, and do not represent a limitation of the scope of the present invention.
    Example 1: Soft gelatin capsules
    The capsules were prepared following conventional procedures.
    Each capsule contained:
    omega-3 fatty acids 572.00 mg
    hyaluronic acid 6.50 mg
    dermatan sulfate 1.34 mg
    nucleotides 300.00 mg
    zinc oxide 13.88 mg
    omega-6 fatty acids 75.00 mg
    Example 2: Soft gelatin capsules with vitamin E
    The capsules were prepared following conventional procedures.
    5
    10
    fifteen
    twenty
    25
    30
    35
    Each capsule contains: omega-3 fatty acids dermatan sulfate hyaluronic acid nucleotides
    300.00 mg
    572.00 mg 6.50 mg 1.34 mg
    zinc oxide omega-6 vitamin E fatty acids
    13.88 mg
    75.00 mg
    18.00 mg
    Example 3: Fibroblast proliferation stimulating activity of a composition of the invention containing omega-3 fatty acids, hyaluronic acid, dermatan sulfate and nucleotides. Comparison with a composition that does not contain nucleotides
    Fibroblasts are, together with keratinocytes, the main cells of the dermis and epidermis. Its migration and proliferation are involved in the re-epithelialization process, very necessary in dermal pathologies in which the dermal barrier is altered and the patients present lesions caused by the pathology itself or by self-scratching due to pruritus. The objective of the present study was to determine the stimulating activity of the proliferation of human dermal fibroblasts of a composition of the present invention that contains omega-3 fatty acids, hyaluronic acid, dermatan sulfate and nucleotides, comparing it with a composition containing omega fatty acids -3, hyaluronic acid and dermatan sulfate. The two compositions were compared to the same final concentration of 0.156 mg / mL.
    A composition of the invention containing 65.38% of omega-3 (O-3) fatty acids, 0.64% of hyaluronic acid (AH), 0.15% of dermatan sulfate (SD) and 34, was used. 13% nucleotides (N) (weight ratio O-3: AH: SD: N 100: 0.98: 0.23: 52.20).
    Materials and methods
    The degree of proliferation was quantified by measuring the incorporation of bromodeoxyuridine (BrdU) during DNA synthesis in proliferating fibroblasts.
    Human dermal fibroblasts were seeded at 5,500 cells / well in 96-well plates and after 6-7 hours they were left with culture medium for growth factor deprivation overnight. The next day, the cells were treated with a composition of the present invention, with a concentration of 0.156 mg / mL, containing omega-3 fatty acids, hyaluronic acid, dermatan sulfate and nucleotides (O-3 + AH + SD + N) or
    5
    10
    fifteen
    twenty
    25
    30
    with a concentration composition 0.156 mg / mL, which contains omega-3 fatty acids, hyaluronic acid and dermatan sulfate (O-3 + AH + SD). The amount of absorbance was determined by spectrophotometry after 48 hours of exposure of the culture to the compositions to be studied.
    As a Basal Control, the cells were not treated; and as a Positive Control, the fibroblasts were exposed to TGF-P1 (25 ng / mL).
    Results
    As can be seen in Figure 1, the composition of the present invention (O-3 + AH + SD + N) at a dose of 0.156 mg / mL and at 48 hours showed a statistically significant stimulatory effect (p = 0.0297) of fibroblast proliferation, if compared with the Basal Control. Specifically, proliferation increased by 40.70%. However, at the same dose of 0.156 mg / mL, the composition containing omega-3 fatty acids, hyaluronic acid and dermatan sulfate (O-3 + AH + SD), but does not contain nucleotides, did not show efficacy (observed a tendency to stimulate fibroblast proliferation, but it was not statistically significant when compared to Baseline Control). Figure 1 also shows the statistically significant difference (p = 0.0263) between the two compositions.
    Example 4: Fibroblast proliferation stimulating activity of a composition of the invention containing omega-3 fatty acids, hyaluronic acid, dermatan sulfate, nucleotides and ZnO. Comparison with a composition that contains neither nucleotides nor ZnO
    The objective of the study was to determine the stimulating activity of the proliferation of human dermal fibroblasts of a composition of the present invention that contains omega-3 fatty acids, hyaluronic acid, dermatan sulfate, nucleotides and ZnO, comparing it with a composition containing fatty acids omega-3, hyaluronic acid and dermatan sulfate. The two compositions were compared to the same final concentration of 0.078 mg / mL.
    A composition of the invention containing 64.10% of omega-3 fatty acids (O-3), 0.76% of hyaluronic acid (AH), 0.12% of dermatan sulfate (SD), 33, was used. 33% of nucleotides (N) and 1.28% of ZnO (weight ratio O-3: AH: SD: N: ZnO 100: 1.20: 0.20: 52: 2).
    Materials and methods
    The same method as in Example 3 was applied, but in this case 24 hours of exposure of the culture to the compositions to be studied were allowed, which were prepared at a final concentration of 0.078 mg / mL.
    5
    Results
    In Figure 2, the statistically significant difference (p = 0.0001) between the composition of the present invention (O-3 + AH + SD + N + ZnO) and at a dose of 0.078 mg / mL can be observed at 24 hours. The composition containing omega-3 fatty acids, hyaluronic acid 10 and dermatan sulfate (O-3 + AH + SD), but contained neither nucleotides nor zinc oxide.
    权利要求:
    Claims (14)
    [1]
    5
    10
    fifteen
    twenty
    25
    30
    35
    1. - A composition comprising hyaluronic acid, dermatan sulfate, at least one omega-3 fatty acid and at least one nucleotide.
    [2]
    2. - The composition according to claim 1, wherein the omega-3 fatty acid and hyaluronic acid are present in a weight ratio omega-3 fatty acid to hyaluronic acid between 100: 0.50 and 100: 5.
    [3]
    3. - The composition according to claim 1 or claim 2, wherein the omega-3 fatty acid and dermatan sulfate are present in a weight ratio omega-3 fatty acid to dermatan sulfate between 100: 0, 10 and 100: 2.
    [4]
    4. - The composition according to any one of claims 1 to 3, wherein the omega-3 fatty acid and the nucleotide are present in a weight ratio omega-3 fatty acid to nucleotide between 100: 20 and 100: 200 .
    [5]
    5. - The composition according to any one of claims 1 to 4, which further comprises zinc oxide.
    [6]
    6. - The composition according to claim 5, wherein the omega-3 fatty acid and zinc oxide are present in a ratio by weight omega-3 fatty acid to zinc oxide between 100: 1 and 100: 10.
    [7]
    7. - The composition according to any one of claims 1 to 6, which further comprises at least one omega-6 fatty acid.
    [8]
    8. - The composition according to any one of claims 1 to 7, wherein the omega-3 fatty acid is selected from the group consisting of eicosapentaenoic acid, docosahexaenoic acid, alpha-linolenic acid, stearidonic acid, eicosatetraenoic acid, acid heneicosapentaenoic, docosapentaenoic acid and mixtures thereof.
    [9]
    9. - The composition according to claim 7 or claim 8, wherein the omega 6 fatty acid is selected from the group consisting of gamma-linolenic acid, linoleic acid and mixtures thereof.
    [10]
    10. - The composition according to any one of claims 1 to 9, wherein the nucleotide is obtained from a yeast.
    [11]
    11. - A food supplement, a functional food or a medical food comprising the composition defined in any one of claims 1 to 10, and at least one additive
    Nutritional
    [12]
    12. - A pharmaceutical composition comprising the composition defined in any one of claims 1 to 10, and at least one pharmaceutically acceptable excipient.
    10
    [13]
    13. - Use of a composition defined in any one of claims 1 to 10, for the preparation of a medicament for the treatment or prevention of a disease or skin lesion selected from the group consisting of atopic dermatitis, allergic dermatitis , demodicosis, psoriasis, wound, ulcer and burn in a mammal.
    fifteen
    [14]
    14. - Use of a composition defined in any one of claims 1 to 10, for the preparation of a food supplement, a functional food or a medical food, to restore the integrity of the skin during or after a dermatitis or a demodicosis, prevent or reverse psoriasic injury, increase hydration and flexibility of
    20 the skin, prevent the formation of a wound or an ulcer or improve the quality of cicatrization
    of a wound, an ulcer or a burn in a mammal.
    类似技术:
    公开号 | 公开日 | 专利标题
    US10449248B2|2019-10-22|Nutritional composition for improving the mammalian immune system
    Alexander et al.2014|Role of arginine and omega-3 fatty acids in wound healing and infection
    US9555063B2|2017-01-31|Pluripotent therapeutic compositions and uses thereof
    ES2346904T3|2010-10-21|NUTRITIVE SUPPLEMENT FOR PATIENTS WITH HIV.
    AU2013221572B2|2017-12-21|Methods, compositions, and devices for supplying dietary fatty acid needs
    US20180133190A1|2018-05-17|Monoacylglycerols and fat-soluble nutrients for use in the treatment of nutrient deficiency from maldigestion
    ES2535213T3|2015-05-06|Use of anabolic agents, anti-catabolic agents, antioxidant agents and analgesics for the protection, treatment and repair of connective tissues in humans and animals
    CN100462080C|2009-02-18|Enteral composition for the prevention and/or treatment of sepsis
    US20160263073A1|2016-09-15|Monoacylglycerols for use in the treatment of malabsorption having a mechanical basis
    ES2638195B1|2018-08-02|SKIN COMPOSITIONS
    US20160303167A1|2016-10-20|Cartilage regeneration-promoting agent
    Toida et al.2006|Immunological activity of chondroitin sulfate
    US20160263072A1|2016-09-15|Monoacylglycerols and fat-soluble nutrients for use in the treatment of malabsorption having a non-mechanical basis
    US20200113858A1|2020-04-16|Human dietary supplement and method for treating digestive system and immune-related disorders
    US9980934B2|2018-05-29|Monoacylglycerols for use in conjunction with a lipase inhibitor and/or diets low in fat and/or calories
    同族专利:
    公开号 | 公开日
    JP6942174B2|2021-09-29|
    US11077136B2|2021-08-03|
    ES2638195B1|2018-08-02|
    EP3445377A1|2019-02-27|
    US20190192553A1|2019-06-27|
    JP2019515685A|2019-06-13|
    EP3445377B1|2021-09-22|
    PT3445377T|2021-12-07|
    WO2017182379A1|2017-10-26|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US20040097404A1|2000-11-17|2004-05-20|Barbara Kessler|Supplement to be enternally administered for parenteral nutrition or partial enteral/oral nurtrition of the critically ill, the chronically ill and people with malnutrition|
    EP1634599A1|2004-08-20|2006-03-15|N.V. Nutricia|Iimmune stimulatory infant nutrition|
    US20110256247A1|2008-12-31|2011-10-20|Nitromega Corp.|Topical compositions containing nitro fatty acids|
    US20140302171A1|2011-10-12|2014-10-09|For Days Co., Ltd|Cysteine Peptide-Containing Health Drink|
    US4780414A|1985-01-18|1988-10-25|Bio-Technology General Corp.|Method of producing high molecular weight sodium hyallronate by fermentation of streptococcus|
    US4784990A|1985-01-18|1988-11-15|Bio-Technology General Corporation|High molecular weight sodium hyaluronate|
    IT1189085B|1986-03-25|1988-01-28|Mediolanum Farmaceutici Srl|PROCESS FOR THE PREPARATION OF HIGH PURITY DERMATAN SULPHATE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT|
    US6558710B1|1999-06-14|2003-05-06|Helen Rebecca Godfrey|Topical zinc compositions and methods of use|
    JP2001163789A|1999-12-13|2001-06-19|Maruho Co Ltd|Medicine composition for matrix metalloprotease inhibitor|
    JP2001169751A|1999-12-17|2001-06-26|Ox:Kk|Mucosaccharide-containing food|
    DE10160933B4|2001-12-12|2018-06-21|Evonik Degussa Gmbh|Deodorizing compositions containing the zinc salt of ricinoleic acid and at least one amino-functional amino acid|
    US7204859B2|2002-12-06|2007-04-17|L'oreal S.A.|Composition for the oxidation dyeing of keratin fibers, comprising at least one fatty alcohol, at least one oxidation dye, at least one associative polymer, and at least one compound chosen from fatty acid esters and metal oxides|
    EP1665940A4|2003-09-02|2011-01-19|Bbk Bio Corp|Diet food|
    US20070129430A1|2003-10-07|2007-06-07|Satomi Miyata|Agent for enhancing the production of collagen, their preparation and use|
    JP2005046133A|2003-10-20|2005-02-24|Medicaraise Corp|Health food containing hyaluronic acid and dermatan sulfate|
    US11039999B2|2004-06-25|2021-06-22|Ferrosan Aps|Compositions suitable for treating cutaneous signs of aging|
    JP2006143605A|2004-11-16|2006-06-08|Miyao Shunsuke|Method for producing percutaneously administrative agent and orally administrative agent each promoting fibroblast proliferation|
    ES2281265B1|2005-11-24|2008-08-16|Bioiberica, S.A.|COMPOSITIONS FOR THE TREATMENT OF ARTROSIS.|
    US7763594B2|2005-11-30|2010-07-27|Bioiberica, S.A.|Compositions for the treatment of osteoarthritis and to nourish the synovial fluid|
    WO2010078504A1|2008-12-31|2010-07-08|Nitromega Corp.|Nutraceuticals containing nitro fatty acids|
    US9006339B2|2011-05-10|2015-04-14|Basf Se|Mechanically stabilized polyazoles comprising at least one polyvinyl alcohol|
    US8540782B2|2011-06-24|2013-09-24|L'oreal|Emulsion dyeing composition containing at least one quarternary amine, at least one nonionic surfactant and at least one carboxylic acid and method of using the same|
    DE202013008190U1|2013-09-17|2013-12-05|Pg Naturpharma Gmbh|Preparation and its use in atopic dermatitis|
    法律状态:
    2018-08-02| FG2A| Definitive protection|Ref document number: 2638195 Country of ref document: ES Kind code of ref document: B1 Effective date: 20180802 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201630479A|ES2638195B1|2016-04-18|2016-04-18|SKIN COMPOSITIONS|ES201630479A| ES2638195B1|2016-04-18|2016-04-18|SKIN COMPOSITIONS|
    PT177169216T| PT3445377T|2016-04-18|2017-04-12|Compositions for the skin|
    PCT/EP2017/058877| WO2017182379A1|2016-04-18|2017-04-12|Compositions for the skin|
    US16/094,300| US11077136B2|2016-04-18|2017-04-12|Compositions for the skin|
    EP17716921.6A| EP3445377B1|2016-04-18|2017-04-12|Compositions for the skin|
    JP2019505283A| JP6942174B2|2016-04-18|2017-04-12|Skin composition|
    [返回顶部]